New FDA Approval: Deucravacitinib (Sotyktu), a First-In-Class Oral, Allosteric Tyrosine Kinase 2 Inhibitor
In September 2022, deucravacitinib (Sotyktu) , a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug. This premium deep dive into deucravacitinib includes: the [...]
In September 2022, deucravacitinib (Sotyktu) , a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-t...